DENVER–(BUSINESS WIRE)–Front Range Pharmaceuticals (“Front Range”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to FRP-003, the company’s investigational drug candidate, for the treatment of Long COVID. FDA’s Division of Rheumatology and Transplant Medicine issued the designation on October 30, 2026, under the company’s investigational new drug application (IND 182511). In its letter, FDA stated that the company’s request, submitted on Au
